Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide

Tomoko Ichiki, Nina Dzhoyashvili, John C. Burnett

Research output: Contribution to journalArticle

3 Scopus citations


Cenderitide is a novel designer natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide was engineered to co-activate the two NP receptors, particulate guanylyl cyclase (pGC)-A and pGC-B. The rationale for its design was to achieve the renal-enhancing and anti-fibrotic properties of dual receptor activation, but without clinically significant hypotension. Here, we review the biology of the NPs and the rationale for their use in heart failure. Most importantly, we present the key studies related to the discovery of Cenderitide. Finally, we review the key clinical studies that have advanced this first-in-class dual NP receptor activator for heart failure.

Original languageEnglish (US)
Pages (from-to)166-171
Number of pages6
JournalInternational Journal of Cardiology
StatePublished - Apr 15 2019



  • Designer natriuretic peptide
  • Drug development
  • Heart failure
  • Natriuretic peptide
  • Receptors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this